相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials
Federica Cuppone et al.
CANCER (2008)
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. C. Coombes et al.
LANCET (2007)
Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients
L Morales et al.
ANNALS OF ONCOLOGY (2005)
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'
G Atalay et al.
ANNALS OF ONCOLOGY (2004)
Exemestane and aromatase inhibitors in the management of advanced breast cancer
JM Dixon
EXPERT OPINION ON PHARMACOTHERAPY (2004)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - Results of the ATAC (arimidex, tamoxifen alone or in comhination) trial efficacy and safety update analyses
CANCER (2003)
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
R Paridaens et al.
ANNALS OF ONCOLOGY (2003)
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:: Analysis of survival and update of efficacy from the international letrozole breast cancer group
H Mouridsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:: Results of a phase III study of the international letrozole breast cancer group
H Mouridsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
JM Nabholtz et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
J Bonneterre et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial
PE Lonning et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
